Alfred Ian Lee MD, PhD

Assistant Professor of Medicine (Hematology); Firm Chief, Inpatient Hematology, Yale Cancer Center; Assistant Program Director, Traditional Internal Medicine Residency Program

Clinical Interests

Lymphoma; platelet disorders; thrombosis; bleeding; coagulation disorders; leukemia


Board Certifications

2007
Internal Medicine, Board Certified
2013
Hematology (Internal Medicine), Board Certified

Patient Care Locations

alfred_leefaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
Hepatic Veno-Occlusive Disease, Hodgkin's Lymphoma, Leukemia, not otherwise specified, Multiple Myeloma, and Non-Hodgkin's LymphomaDefibrotide for Patients with Hepatic Veno-Occlusive Disease (VOD): A Treatment IND Study
Myeloid and Monocytic LeukemiaA Randomized Phase III Study of Standard Cytarabine Plus Daunomycin (7+3) Therapy versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Antiphospholipid Syndrome (APS)Comparison of Gut Commensal Bacteria Between Persistently anti-gamma2 Glycoprotein-I Positive Patients and Antiphospholipid Antibody Negative Patients
Non-Hodgkin's LymphomaA randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30- positive mature T-cell lymphomas
Leukemia, not otherwise specified and Myeloid and Monocytic LeukemiaAn Open Label, Phase I/IIa, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Intravenous Volasertib (BI 6727) in Combination with Decitabine in Patients with Acute Myeloid Leukemia

More Clinical Trials...

Edit Profile